• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    11/1/23 1:31:20 PM ET
    $ALDX
    $CLLS
    $CWBR
    $DTIL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALDX alert in real time by email

    Gainers

    • Cellectis (NASDAQ:CLLS) shares moved upwards by 188.6% to $2.8 during Wednesday's regular session. Trading volume for this security as of 13:31 EST is 58.7 million, which is 110697.6% of its average full-day volume over the last 100 days. The company's market cap stands at $155.6 million.
    • Aldeyra Therapeutics (NASDAQ:ALDX) shares rose 50.74% to $2.58. Aldeyra Therapeutics's stock is trading at a volume of 58.1 million shares as of 13:31 EST. This is 5356.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $151.0 million.
    • Monopar Therapeutics (NASDAQ:MNPR) stock increased by 37.51% to $0.59. As of 13:31 EST, this security is trading at a volume of 47.8 million shares, making up 32194.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $8.3 million.
    • TG Therapeutics (NASDAQ:TGTX) shares rose 31.95% to $10.2. The current volume of 41.9 million shares is 796.4% of TG Therapeutics's average full-day volume over the last 100 days (last updated at 13:31 EST). The company's market cap stands at $1.5 billion. The company's, Q3 earnings came out today.
    • Silence Therapeutics (NASDAQ:SLN) stock moved upwards by 30.59% to $8.75. The current volume of 87.0K shares is 136.0% of Silence Therapeutics's average full-day volume over the last 100 days (last updated at 13:31 EST). The company's market cap stands at $321.5 million.
    • Precision BioSciences (NASDAQ:DTIL) shares rose 25.4% to $0.39. Trading volume for this security as of 13:31 EST is 2.6 million, which is 249.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $44.4 million.

    Losers

    • CohBar (NASDAQ:CWBR) stock declined by 48.9% to $0.92 during Wednesday's regular session. As of 13:31 EST, this security is trading at a volume of 255.6K shares, making up 1693.3% of its average full-day volume over the last 100 days. The company's market cap stands at $2.6 million.
    • Iridex (NASDAQ:IRIX) stock decreased by 34.61% to $2.15. Iridex's stock is trading at a volume of 1.6 million shares as of 13:31 EST. This is 1965.2% of its average full-day volume over the last 100 days. The company's market cap stands at $34.8 million.
    • Kintara Therapeutics (NASDAQ:KTRA) stock fell 33.25% to $0.51. The current volume of 1.8 million shares is 3306.6% of Kintara Therapeutics's average full-day volume over the last 100 days (last updated at 13:31 EST).
    • Tenon Medical (NASDAQ:TNON) shares declined by 25.99% to $0.1. Tenon Medical's stock is trading at a volume of 846.1K shares as of 13:31 EST. This is 61.2% of its average full-day volume over the last 100 days. The company's market cap stands at $2.3 million.
    • G1 Therapeutics (NASDAQ:GTHX) stock declined by 19.39% to $1.33. G1 Therapeutics's stock is trading at a volume of 836.8K shares as of 13:31 EST. This is 109.4% of its average full-day volume over the last 100 days. The company's market cap stands at $68.8 million. As per the press release, Q3 earnings came out today.
    • Stevanato Gr (NYSE:STVN) shares declined by 16.37% to $23.38. The current volume of 588.4K shares is 173.4% of Stevanato Gr's average full-day volume over the last 100 days (last updated at 13:31 EST). The company's market cap stands at $6.9 billion. As per the press release, Q3 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALDX
    $CLLS
    $CWBR
    $DTIL

    CompanyDatePrice TargetRatingAnalyst
    Aldeyra Therapeutics Inc.
    $ALDX
    3/18/2026$2.00Buy → Neutral
    H.C. Wainwright
    Cellectis S.A.
    $CLLS
    2/17/2026$7.00Buy
    Jefferies
    Monopar Therapeutics Inc.
    $MNPR
    1/9/2026$115.00Overweight
    Morgan Stanley
    Stevanato Group S.p.A.
    $STVN
    12/2/2025$24.00Equal-Weight
    Morgan Stanley
    Monopar Therapeutics Inc.
    $MNPR
    11/14/2025Strong Buy → Outperform
    Raymond James
    Monopar Therapeutics Inc.
    $MNPR
    11/10/2025$115.00Outperform
    Leerink Partners
    Monopar Therapeutics Inc.
    $MNPR
    10/13/2025$125.00Overweight
    Barclays
    TG Therapeutics Inc.
    $TGTX
    10/6/2025$60.00Buy
    H.C. Wainwright
    More analyst ratings

    $ALDX
    $CLLS
    $CWBR
    $DTIL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Dizon Romeo R bought $1,399 worth of shares (1,110 units at $1.26), increasing direct ownership by 0.93% to 121,000 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    3/9/26 1:05:37 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Dizon Romeo R bought $2,942 worth of shares (2,200 units at $1.34), increasing direct ownership by 2% to 119,890 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    2/17/26 12:55:35 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Dizon Romeo R bought $2,145 worth of shares (1,500 units at $1.43), increasing direct ownership by 1% to 117,690 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    2/12/26 10:05:32 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ALDX
    $CLLS
    $CWBR
    $DTIL
    SEC Filings

    View All

    Amendment: SEC Form D/A filed by IRIDEX Corporation

    D/A - IRIDEX CORP (0001006045) (Filer)

    4/3/26 2:42:25 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-K filed by IRIDEX Corporation

    10-K - IRIDEX CORP (0001006045) (Filer)

    4/2/26 4:20:06 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 8-K filed by Aldeyra Therapeutics Inc.

    8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

    4/1/26 4:25:05 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $CLLS
    $CWBR
    $DTIL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

    10/31/24 4:38:40 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:

    12/28/22 12:54:09 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for COSELA

    Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB DIHYDROCHLORIDE has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity

    2/16/21 4:31:16 PM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $CLLS
    $CWBR
    $DTIL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

    WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar," the "Company," "we") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the fourth quarter and full-year 2025 financial results and provided a summary of recent developments. "2025 was a productive year for Monopar, marked by multiple ALXN1840 data presentations, an important publication, a strengthened balance sheet and continued progress toward a planned New Drug Application submission for ALXN1840 in Wilson disease," said Chandler Robinson, MD, Chief Executive Officer of Monopar. "We also recently strengt

    3/27/26 1:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Iridex Reports Fourth Quarter and Full Year 2025 Financial Results

    MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Financial Highlights Generated total revenue of $14.7 million, representing growth of 16% year-over-year compared to $12.7 million in the prior year quarterCyclo G6® product family revenue was $3.8 million, representing growth of 15% year-over-year compared to $3.3 million in the prior year quarter Sold 15,900 Cycl

    3/26/26 4:05:00 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers

    Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than $16 billion in worldwide sales TAMPA, Fla., March 23, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced Dr. Craig L. Tendler will provide strat

    3/23/26 7:45:00 AM ET
    $HURA
    $KTRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $CLLS
    $CWBR
    $DTIL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Novel Inspiration International Co., Ltd.

    4 - IRIDEX CORP (0001006045) (Issuer)

    4/3/26 1:55:32 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Robinson Chandler

    4 - Monopar Therapeutics (0001645469) (Issuer)

    4/2/26 3:03:36 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Cittadine Andrew

    4 - Monopar Therapeutics (0001645469) (Issuer)

    4/2/26 3:03:03 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $CLLS
    $CWBR
    $DTIL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aldeyra Therapeutics downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Aldeyra Therapeutics from Buy to Neutral and set a new price target of $2.00

    3/18/26 8:20:05 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Cellectis with a new price target

    Jefferies resumed coverage of Cellectis with a rating of Buy and set a new price target of $7.00

    2/17/26 7:48:16 AM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Monopar Therapeutics with a new price target

    Morgan Stanley initiated coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $115.00

    1/9/26 9:05:54 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $CLLS
    $CWBR
    $DTIL
    Leadership Updates

    Live Leadership Updates

    View All

    Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

    WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar" or the "Company"), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company's commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson d

    3/2/26 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Silence Therapeutics Announces Leadership Changes

    Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has served as the Company's President, Chief Executive Officer and Board member since 2022, agreed by mutual consent to end his employment with the Company effective 14 December 2025. Iain Ross, Chairman of the Silence Board, will lead the Company with immediate effect on an interim basis. Additionally, James Ede Golightly, a former Silence Non-Executive Director, has been re-appointed to the Company's Board of Directors. An additional appointment of an US-based Board member is anticipated in due

    12/15/25 8:13:00 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Silence Therapeutics Welcomes Tim McInerney to Board of Directors

    Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced the appointment of Tim McInerney to the Company's Board of Directors, effective immediately. Mr. McInerney will stand for re-appointment to the Silence Board at the Annual General Meeting ("AGM") in June 2025. "We are thrilled to welcome Tim to the Silence Board," said Iain Ross, Chairman of the Silence Board. "Tim is a seasoned executive and board memb

    5/6/25 7:45:00 AM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $CLLS
    $CWBR
    $DTIL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by TG Therapeutics Inc.

    SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

    11/14/24 7:45:34 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Precision BioSciences Inc.

    SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)

    11/14/24 4:50:29 PM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALDX
    $CLLS
    $CWBR
    $DTIL
    Financials

    Live finance-specific insights

    View All

    Iridex Reports Fourth Quarter and Full Year 2025 Financial Results

    MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Financial Highlights Generated total revenue of $14.7 million, representing growth of 16% year-over-year compared to $12.7 million in the prior year quarterCyclo G6® product family revenue was $3.8 million, representing growth of 15% year-over-year compared to $3.3 million in the prior year quarter Sold 15,900 Cycl

    3/26/26 4:05:00 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

    NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") ((Euronext Growth: ALCLS, NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2025 ending December 31, 2025 on Thursday, March 19, 2026 after the close of the US market. The publication will be followed by an investor conference call and webcast on Friday, March 20, 2026, at 8:00 AM ET / 1:00 PM CET. The call will include the Company's fourth quarter and full year 2025 results and an update on business activities. Details for the call are

    3/12/26 4:30:00 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026

    MOUNTAIN VIEW, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the fourth quarter and full year 2025 and provide a business update after the close of trading on March 26, 2026. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-646-307-1963 from the US or +1-800-715-9871 internationally and pro

    3/12/26 4:05:00 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ALDX
    $CLLS
    $CWBR
    $DTIL
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care